Most people taking tirzepatide lose between 16% and 22.5% of their body weight over about a year and a half, depending on the dose. For someone starting at 230 pounds, that translates to roughly 35 to 52 pounds. These numbers come from the SURMOUNT-1 trial, the largest clinical study of tirzepatide for weight loss, which tracked participants without diabetes over 72 weeks.
Weight Loss by Dose
Tirzepatide is prescribed at three maintenance doses: 5 mg, 10 mg, and 15 mg, all given as a weekly injection. Each dose produces meaningfully different results. In SURMOUNT-1, participants on the 5 mg dose lost an average of 16% of their body weight (about 35 pounds). Those on 10 mg lost 21.4% (around 49 pounds). And the highest dose, 15 mg, produced an average loss of 22.5%, or roughly 52 pounds. The placebo group, for comparison, lost just 2.4%.
These are averages, which means some people lost more and some lost less. Over a third of participants on the 15 mg dose lost 25% or more of their starting weight. That’s a level of weight loss previously only seen with bariatric surgery.
How Quickly the Weight Comes Off
You won’t start at the full dose. Tirzepatide begins at 2.5 mg per week, then increases by 2.5 mg every four weeks until you and your prescriber settle on a maintenance dose. This gradual escalation takes at least 12 to 16 weeks, and the weight loss accelerates as the dose climbs.
In the SURMOUNT-3 trial, participants who had already lost at least 5% of their body weight through diet and exercise went on to lose an additional 18.4% after starting tirzepatide. The weight loss continued steadily through the full 72-week treatment period, with most of the reduction happening in the first year before gradually plateauing.
How Tirzepatide Compares to Semaglutide
Semaglutide (sold as Wegovy for weight loss) works on one gut hormone pathway. Tirzepatide targets two. That difference shows up in the results: semaglutide produces an average weight loss of about 15% over a similar timeframe, while tirzepatide at the highest dose reaches 22.5%. That gap of roughly 5 to 7 percentage points is consistent across trials, giving tirzepatide a notable edge in total weight lost.
Why It Works
Tirzepatide mimics two hormones your gut naturally releases after eating. One, called GLP-1, signals fullness to your brain through the hypothalamus and slows the speed at which food leaves your stomach. The slower emptying keeps you feeling satisfied longer and blunts the blood sugar spikes that follow meals. The second hormone, GIP, amplifies the appetite-suppressing effects of GLP-1 by activating separate neurons in the brain. This dual action is why tirzepatide tends to outperform medications that only target one of these pathways.
The practical effect is straightforward: you feel less hungry, you feel full sooner, and food is less preoccupying. People often describe a quieting of the constant mental noise around eating.
Changes Beyond the Scale
The weight loss from tirzepatide comes with measurable improvements in metabolic health. A systematic review found that all three doses significantly reduced waist circumference, triglycerides, and harmful cholesterol particles while raising HDL (the protective kind). Blood pressure and blood sugar control also improved across trials. These changes reduce your risk of heart disease, stroke, and type 2 diabetes, which is part of why the medication is prescribed in the first place.
Side Effects to Expect
Gastrointestinal symptoms are the most common downside, and they’re not subtle. Between 30% and 40% of people experience nausea, 20% to 25% deal with diarrhea, and 15% to 18% have vomiting. Constipation affects 12% to 15%. These side effects are usually worst during dose increases and tend to fade as your body adjusts. The slow titration schedule exists specifically to minimize these symptoms, though some people still find certain doses hard to tolerate.
What Happens If You Stop
This is the part many people don’t anticipate. A large meta-analysis published in The BMJ found that after stopping weight management medications, people regain weight at an average rate of about 0.9 pounds per month. At that pace, the projected return to baseline weight is roughly 1.7 years after stopping treatment. That doesn’t mean every pound comes back for every person, but the trend is consistent: the biological signals that tirzepatide suppresses return when the medication stops, and appetite gradually reverts to its previous baseline.
This is why most prescribers frame tirzepatide as a long-term or indefinite treatment rather than a short course. The weight loss is real, but maintaining it typically requires staying on the medication or making substantial, sustained changes to diet and activity levels.
Who Can Get a Prescription
Tirzepatide for weight loss is sold under the brand name Zepbound. The FDA approved it for adults with a BMI of 30 or higher, or a BMI of 27 or higher if you also have at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease. It’s meant to be used alongside a reduced-calorie diet and increased physical activity, not as a standalone fix.